Pulmonary Arterial Hypertension & increased dose of Opsumit
Trial Objectives
The UNISUS study will compare the effectiveness and safety of a higher dose of an investigational medication called Opsumit to a lower dose in people with pulmonary arterial hypertension (PAH). The results of the UNISUS Study will provide more information about the investigational medication’s effectiveness and safety when it is given as a higher dose to adults with PAH. Participants will be randomly assigned to receive a tablet of 10 mg or 75 mg dose of Opsumit to take once a day. During clinic visits, participants may have their vital signs taken, provide a blood sample and perform a walking test.
Who Can Participate
Patients diagnosed with pulmonary arterial hypertension
Age: 18+ Gender: Any
Estimated Time Commitment
Up to 4 years. Year 1: monthly visits. Year 2: visits every three months. Years 3-4: visits every six months.
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Contact
For more information, contact:
Jennifer Underwood
303.398.1518
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Janssen Pharmaceuticals
Co-Investigators
-
Marjorie Patricia George, MD
-
Vera Pillitteri, DNP, FNP-BC